ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00388063
Recruitment Status : Completed
First Posted : October 13, 2006
Last Update Posted : December 21, 2007
Sponsor:
Information provided by:
Callisto Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : September 2007